%0 Journal Article
%T Antiretroviral Therapy in Pregnancy: A 2023 Review of the Literature.
%A Goulding AN
%A Meeks K
%A Shay L
%A Casey S
%A Applegarth C
%A McKinney J
%J Curr HIV/AIDS Rep
%V 21
%N 1
%D 2024 02 26
%M 38277098
%F 5.495
%R 10.1007/s11904-024-00688-y
%X Selection of antiretroviral therapy during pregnancy must consider maternal physiology and resulting pharmacokinetic changes in pregnancy, resistance and efficacy profiles, tolerability and frequency of adverse effects, teratogenicity, and maternal, neonatal, and pregnancy outcomes. The objective of this review is to summarize the underlying data that informs the current clinical perinatal guidelines in the USA.<BR>Data now supports the use of dolutegravir at all stages of pregnancy with no significant increase in neural tube defects. Safety and pharmacokinetic data on newer antiretroviral medications in pregnancy continue to lag behind the general population. While there are multiple safety and tolerability concerns with older regimens, there are now multiple options of regimens that are highly efficacious and have good safety data in pregnancy. Most pregnant patients who are virally suppressed on a well-tolerated regimen are able to safely continue those medications during pregnancy.